|
Market Closed -
Other stock markets
|
Pre-market 07:04:42 | |||
| 104.50 EUR | +0.10% |
|
104.15 | -0.33% |
| 12-04 | Biomerieux Launches Leading Endocrinology Testing Offer Dedicated to Enhancing Equine Health | CI |
| 12-04 | BioMérieux Launches Two Dedicated Equine Tests |
| Capitalization | 12.34B 14.37B 11.54B 10.78B 19.89B 1,292B 21.64B 134B 52.13B 612B 53.92B 52.78B 2,247B | P/E ratio 2025 * |
26.6x | P/E ratio 2026 * | 21.8x |
|---|---|---|---|---|---|
| Enterprise value | 12.01B 13.99B 11.23B 10.49B 19.36B 1,257B 21.07B 130B 50.75B 596B 52.49B 51.38B 2,187B | EV / Sales 2025 * |
2.93x | EV / Sales 2026 * | 2.66x |
| Free-Float |
36.04% | Yield 2025 * |
0.87% | Yield 2026 * | 1.11% |
More valuation ratios
* Estimated data
More news
Last Transcript: bioMérieux
More recommendations
More press releases
More news
| 1 day | +0.10% | ||
| 1 week | -1.69% | ||
| Current month | -3.15% | ||
| 1 month | -1.88% | ||
| 3 months | -9.60% | ||
| 6 months | -14.34% | ||
| Current year | +0.97% |
| 1 week | 103.6 | 106 | |
| 1 month | 103.6 | 110.3 | |
| Current year | 101.7 | 128.3 | |
| 1 year | 99.95 | 128.3 | |
| 3 years | 84.54 | 128.3 | |
| 5 years | 77.48 | 133.2 | |
| 10 years | 32.39 | 144.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pierre Boulud
CEO | Chief Executive Officer | 54 | 30/06/2023 |
| Director of Finance/CFO | 49 | 28/02/2018 | |
Charles Cooper
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 76 | 31/12/2013 | |
| Chairman | 51 | 14/12/2017 | |
| Director/Board Member | 65 | 31/12/2004 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.10% | -1.69% | +6.63% | +7.78% | 14.37B | ||
| -0.57% | -3.15% | +188.83% | +121.12% | 13.22B | ||
| -0.18% | -0.51% | - | - | 7.65B | ||
| -2.02% | -2.53% | -15.31% | +22.78% | 6.46B | ||
| -0.10% | +1.76% | -33.15% | +14.09% | 4.03B | ||
| 0.00% | +1.36% | -41.09% | -53.14% | 3.85B | ||
| +0.20% | -1.52% | -20.86% | -41.02% | 2.89B | ||
| +0.30% | -1.86% | -5.95% | -37.36% | 2.39B | ||
| +4.03% | +3.74% | +219.65% | +100.61% | 2.39B | ||
| -1.74% | -1.90% | +8.54% | -49.81% | 2.22B | ||
| Average | +0.36% | -0.28% | +34.14% | +9.45% | 5.95B | |
| Weighted average by Cap. | -0.10% | -1.19% | +51.54% | +31.55% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 4.09B 4.77B 3.83B 3.58B 6.6B 429B 7.18B 44.39B 17.3B 203B 17.89B 17.51B 746B | 4.39B 5.12B 4.11B 3.84B 7.08B 460B 7.7B 47.63B 18.56B 218B 19.2B 18.79B 800B |
| Net income | 466M 543M 436M 407M 751M 48.78B 817M 5.05B 1.97B 23.12B 2.04B 1.99B 84.86B | 564M 656M 527M 492M 909M 59B 989M 6.11B 2.38B 27.97B 2.46B 2.41B 103B |
| Net Debt | -328M -382M -307M -287M -529M -34.35B -576M -3.56B -1.39B -16.28B -1.43B -1.4B -59.75B | -666M -776M -623M -582M -1.07B -69.76B -1.17B -7.23B -2.82B -33.07B -2.91B -2.85B -121B |
More financial data
* Estimated data
Employees
14,451
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/12/25 | 104.50 € | +0.10% | 98,320 |
| 09/12/25 | 104.40 € | +0.10% | 94,543 |
| 08/12/25 | 104.30 € | -0.48% | 111,150 |
| 05/12/25 | 104.80 € | +0.58% | 181,034 |
| 04/12/25 | 104.20 € | -1.98% | 150,407 |
Real-time Euronext Paris, December 10, 2025 at 04:55 pm
More quotesSell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
104.50EUR
Average target price
123.46EUR
Spread / Average Target
+18.15%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BIM Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition


















